Search

Your search keyword '"Wu, Kaihan"' showing total 17 results
Start Over Author "Wu, Kaihan"
17 results on '"Wu, Kaihan"'

2. Ensemble Learning for Crowdfunding Dynamics: JingDong Crowdfunding Projects

Author

Min, Hu, Wu, Kaihan, Tan, Minghao, Lin, Junyan, Zheng, Yufan, Zhan, Choujun, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Prates, Raquel Oliveira, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Zhang, Haijun, editor, Chen, Yuehui, editor, Chu, Xianghua, editor, Zhang, Zhao, editor, Hao, Tianyong, editor, Wu, Zhou, editor, and Yang, Yimin, editor

Published
2022
Full Text
View/download PDF

15. Nontarget Analysis of Legacy and Emerging PFAS in a Lithium-Ion Power Battery Recycling Park and Their Possible Toxicity Measured Using High-Throughput Phenotype Screening

Author

Qi, Zenghua, Cao, Yutian, Li, Dan, Wu, Chenguang, Wu, Kaihan, Song, Yuanyuan, Huang, Zeji, Luan, Hemi, Meng, Xiaojing, Yang, Zhu, and Cai, Zongwei

Abstract

Driven by the global popularity of electric vehicles and the shortage of critical raw materials for batteries, the spent lithium-ion power battery (LIPB) recycling industry has exhibited explosive growth in both quantity and scale. However, relatively little information is known about the environmental risks posed by LIPB recycling, in particular with regards to perfluoroalkyl and polyfluoroalkyl substances (PFAS). In this work, suspect screening and nontarget analysis were carried out to characterize PFAS in soil, dust, water and sediment from a LIPB recycling area. Twenty-five PFAS from nine classes were identified at confidence level 3 or above, including 13 legacy and 12 emerging PFAS, as well as two ultrashort-chain PFAS. Based on the target analysis of 16 PFAS, at least nine were detected in each environmental sample, indicating their widespread presence in a LIPB recycling area. Perfluorodecanoic acid, perfluorooctanesulfonic acid and trifluoromethanesulfonamide showed significant differences in the four phenotypic parameters (growth, movement, survival and fecundity) of Caenorhabditis elegansand were the most toxic substances in all target PFAS at an exposure concentration of 200 μM. Our project provides first-hand information on the existence and environmental risk of PFAS, facilitating the formulation of regulations and green development of the LIPB recycling industry.

Published
2024
Full Text
View/download PDF

16. Association of circulating visfatin level and metabolic fatty liver disease: An updated meta-analysis and systematic review.

Author

Chen S, Wu K, Ke Y, Chen S, He R, Zhang Q, Shen C, Li Q, Ruan Y, Zhu Y, Du K, Hu J, and Liu S

Subjects
Humans, Biomarkers blood, Early Diagnosis, Obesity blood, Obesity diagnosis, Obesity metabolism, Cytokines blood, Nicotinamide Phosphoribosyltransferase blood, Non-alcoholic Fatty Liver Disease blood, Non-alcoholic Fatty Liver Disease diagnosis, Non-alcoholic Fatty Liver Disease metabolism
Abstract

Background: The rate of incidence of metabolic dysfunction-related fatty liver disease (MAFLD) has rapidly increased globally in recent years, but early diagnosis is still a challenge. The purpose of this systematic review and meta-analysis is to identify visfatin for early diagnosis of MAFLD., Methods: We strictly adhered to the relevant requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The systematic search was conducted in 7 sources (PubMed, Embase, Cochrane Library, CNKI, Wanfang, CBM, and ClinicalTrials.gov) until February 2024. The meta-analysis was performed using Stata 12. Outcomes were expressed in the form of standardized mean difference (SMD) and 95% confidence interval and were analyzed using meta-analysis., Results: The results showed that there was no significant difference in circulating visfatin levels between patients with MAFLD and controls (SMD = 0.13 [-0.34, 0.60]). However, the outcomes indicated that the level of circulating visfatin was significantly higher in MAFLD patients in the Middle Eastern subgroup (SMD = 0.45 [0.05, 0.85]) and in the obese patient subgroup (SMD = 1.05 [0.18, 1.92]). No publication bias was detected, and sensitivity analysis confirmed the stability of the outcomes., Conclusion: The serum visfatin levels of MAFLD patients did not differ significantly from those of controls. However, visfatin concentrations in serum were statistically higher within Middle Eastern or obese MAFLD patients compared to controls. There is a need for further research to investigate visfatin's potential as a biomarker for MAFLD., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results